Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

In Vivo Evaluation of Injected and Bioprinted Hyaluronic Acid-Based Bioink in Corneal Stromal Pocket.

Kethiri AR., Puistola P., Huuskonen M., Huhtanen S., Hopia K., Miettinen S.

Animal Study on Scar, Chronic Inflammation, published in Macromol Biosci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Macromol Biosci (2026)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
41548128
PMCID
PMC12812298
DOI
10.1002/mabi.202500555

Abstract (original English)

The corneal stroma contains specialized stromal keratocytes (CSKs) that preserve corneal transparency and homogeneity. Stromal scarring and opacities lead to vision loss in millions globally. While corneal transplantation remains the gold standard, it is constrained by donor shortages. Cell-based therapies using primary stromal cells show promise but still depend on donor tissue. Human adipose tissue-derived stem cells (hASCs) offer an abundant alternative, capable of differentiating into CSKs. A three-dimensional (3D) tissue matrix is essential for mimicking native tissue and supporting stromal regeneration. Hyaluronic acid (HA)-based matrices emerge as promising stromal substitutes. In this study, we aim to investigate the biocompatibility of HA-based bioink, both as injectable formulations and bioprinted constructs containing hASC-CSKs. In vitro, bioprinted HA-based constructs containing hASC-CSKs exhibit high cell viability, an organized structure, and maintained transparency. In vivo, the bioink integrates progressively into the corneal stroma, considerably reducing stromal thickness within two weeks. It supports the hASC-CSK phenotype post-transplantation, as indicated by lumican expression. Although inflammatory responses are observed, the bioink shields transplanted cells from immune rejection, promoting graft survival and integration. These findings demonstrate that HA

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Hyaluronic AcidHumansCorneal StromaAnimalsBioprintingAdipose TissueInkStem CellsCell SurvivalLumican

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research